Table 1.
Comparison of clinical and pathological characteristics according to preoperative risk group.
Table 2.
Comparison of the Survival Models’ Performance.
Fig 1.
Kaplan-Meier estimates of biochemical recurrence–free survival (BCRFS) after radical prostatectomy (RP) by the presence of adverse pathological findings (APFs) for (A) total (log-rank test, p <0.001), (B) low-risk (p = 0.027), (C) intermediate-risk (p <0.001), and (D) high-risk (p <0.001) patients.
Table 3.
Multivariate Cox regression analysis of biochemical recurrence according to preoperative risk group.
Fig 2.
Cumulative incidence estimates of prostate cancer-specific mortality (PCSM) after radical prostatectomy (RP) using a competing risk analysis by adverse pathological findings (APFs) for (A) total (Gray’s modified log rank, p = 0.001), (B) low-risk (p = 0.903), (C) intermediate-risk (p = 0.253), and (D) high-risk (p = 0.010) patients.
Table 4.
Multivariate competing risk regression analysis of prostate cancer-specific mortality in overall patients and the high-risk group.